Chemours/$CC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Chemours

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

Ticker

$CC
Sector

Primary listing

NYSE

Employees

6,000

Chemours Metrics

BasicAdvanced
$2.4B
-
-$2.75
1.59
$0.84
2.15%

What the Analysts think about Chemours

Analyst ratings (Buy, Hold, Sell) for Chemours stock.

Bulls say / Bears say

Chemours, DuPont and Corteva’s settlement of New Jersey PFAS claims for $875 million over 25 years (present value ~$500 million pre-tax) removes a major legacy liability, clearing a path to focus on core businesses (Reuters)
Thermal & Specialized Solutions segment delivered 15% year-over-year net sales growth to $597 million, led by a 65% increase in Opteon™ refrigerant volumes under the U.S. AIM Act transition, driving segment EBITDA up 29% to $207 million (Business Wire)
Adjusted earnings per share of $0.58 in Q2 2025 surpassed the $0.46 consensus estimate, alongside a 4% rise in net sales to $1.6 billion, underscoring improved underlying profitability and operational execution (TradingView)
Net loss of $381 million in Q2 2025, or $2.54 per diluted share, was driven by $257 million of litigation-related charges from the New Jersey PFAS settlement, weighing on reported earnings and cash flows (Business Wire)
Titanium Technologies segment adjusted EBITDA plunged 43% year-over-year to $47 million, with margins collapsing to 7%, due to lower pricing and $15 million in incremental costs from a rail line disruption, highlighting ongoing operational vulnerabilities (Business Wire)
As of June 30, 2025, Chemours carried $4.2 billion in gross debt (net debt $3.7 billion) with a trailing twelve-month net leverage ratio of 4.7x, constraining financial flexibility and increasing interest burden (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.

Chemours Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Chemours Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Sept12
Chemours
DividendPayment
$0.0875Per share
FAQs